Jonathan P. Mow
-
Malvern’s PhaseBio Awarded $2.8 Million Grant from National Institutes of Health
PhaseBio Pharmaceuticals, a clinical-stage biopharmaceutical company developing therapies for the treatment of orphan diseases, has been awarded a $2.8 million grant. The Fast Track Small…
-
Malvern’s PhaseBio Raises $15 Million, Shifts Toward New Drug for Orphan Diseases
Malvern’s PhaseBio Pharmaceuticals has switched its focus from diabetes treatments to orphan diseases by closing a nearly $15 million round of financing to help advance…
-
PhaseBio Closes Refinancing With AstraZeneca To Further Drug Trials
PhaseBio Pharmaceuticals, Inc. of Malvern has closed a $40 million Series C financing round led by AstraZeneca. The clinical-stage biopharmaceutical firm is focused on biopolymer-based…
Pioneer Partner
Founding Partners
Advertisement
Affiliate Partners
Community Partners
